Navigation Links
ProNAi Announces Preclinical Success for PNT2258 Therapeutic -,Curative Events in Xenograft Mice for Difficult-to-Treat,Non-Hodgkin's Lymphoma

LOS ANGELES--(BUSINESS WIRE)--Apr 17, 2007 - ProNAi Therapeutics, Inc., a biopharmaceutical company pioneering a new class of nucleic-acid drugs based on DNA interference (DNAi), today announced that its lead oncology therapeutic candidate, PNT2258, has successfully demonstrated preclinical in vivo efficacy in xenograft mice for a number of human cancers - including curative events for difficult-to-treat Burkitt's Lymphoma.

Dr. Richard D. Gill, President and CEO of ProNAi, said, "Team ProNAi is quite pleased with our early preclinical results for PNT2258. Particularly encouraging is the fact that PNT2258 has shown promising single agent efficacy and combination therapy efficacy and drug-dose response for multiple cancer types including both hematological and solid tumors."

He added, "However, a very exciting development was our discovery that PNT2258, in combination with Rituximab, demonstrated curative events in treating Daudi xenografts of human Burkitt's Lymphoma in mice. The antitumor effect was rapid and durable. We had 70% complete remissions in two groups of animals dosed with PNT2258 and Rituximab."

In developing its DNAi(R)-based therapy, ProNAi reports that its successful establishment of in vivo efficacy for formulated PNT2258 included:

-- Single agent efficacy for DLCL2 Xenografts of Human Non-Hodgkin's Lymphoma

-- Combination therapy efficacy with Docetaxel for Human Hormone Refractory Prostate Cancer Xenograft

-- Combination therapy with Rituximab in Daudi Xenografts of Human Burkitt's Lymphoma

ProNAi's preclinical research will proceed in 2007. Planned studies include IND-enabling toxicology and ADME studies. ProNAi will file the IND for PNT2258 later this year.

About DNAi(R)

DNAi(R) (DNA interference) is a novel approach to targeting genomic DNA using sequence-specific therapeutic oligonucleotides, employing single strands of DNA to target and treat non-transcribed regions of genomes responsible for complex genetic diseases, such as cancer.

By acting at the DNA level, where only one or two copies of the gene exist per cell, treatment can be targeted more efficiently by DNAi(R) drugs. With fewer targets, the activity of a DNAi(R) drug is expected to last longer at lower doses, and reduce some of the toxicity issues prevalent with other marketed therapies. Additionally, DNA-related therapies are potentially more cost effective to produce.

About ProNAi Therapeutics, Inc.

ProNAi Therapeutics, Inc. is a biopharmaceutical drug development company pioneering a new class of nucleic-acid drugs based on DNA interference (DNAi(R)), which employs single strands of DNA to target and treat non-transcribed regions of genomes responsible for complex genetic diseases. ProNAi is currently developing multiple DNAi(R)-based drug candidates with the potential to treat multiple cancers, including non-Hodgkin's lymphoma, prostate, breast, and colon cancers. The company's lead drug candidate, PNT2258, which has demonstrated in vivo efficacy in a variety of human tumor xenograft models, is currently in preclinical development. ProNAi is also exploring the potential of DNAi(R)-based therapies for indications such as diabetes, Alzheimer's and inflammatory disease.

ProNAi is based in Kalamazoo, Michigan. For more information, please visit: www.pronai.com.

Contact

Aviator PR
Mario Fante, 617-763-9887
mario@aviator-pr.com


'"/>




Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... 2016  The Parenteral Drug Association, Inc. (PDA), ... manufacturing sterile drug products, today announced the publication ... – With link to Comparison Spreadsheet. The ... U.S. FDA, the EU, the Pharmaceutical Inspection Convention/Scheme ... --> --> PDA,s Global Sterile ...
(Date:2/8/2016)... Feb.8, 2016 Cardiovascular Surgery Devices - ... GlobalData,s Medical Devices sector report, "Cardiovascular Surgery Devices ... overview of Cardiovascular Surgery Devices currently in pipeline ... The report provides comprehensive information on the ... at various stages of development. The report reviews ...
(Date:2/8/2016)... FAIRFIELD, N.J. , Feb. 8, 2016  Otsuka ... today announced that they have entered into a licensing ... OPA-15406 in the U.S. and Puerto Rico ... is a topical, non-steroidal phosphodiesterase IV (PDE-4) inhibitor, a ... --> --> In a Phase II ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... February 08, 2016 , ... Stephanie Hebert Insurance ... beginning of a new charity campaign. As part of their ongoing community involvement ... In the belief that children deserve a voice, and in the spirit of ...
(Date:2/8/2016)... ... February 08, 2016 , ... Tingley ... into Canada to provide its range of unique and advantaged protective solutions ... City that will provide bilingual customer service and marketing support. A new distribution ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... announced today that nominations will be accepted February 8, 2016 through May ... , Awards include the Information Security Executive® of the Year, which recognizes ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... lower incidence rate of type 2 diabetes in the GrassrootsHealth cohort with substantially ... to make a change in public health,” states Carole Baggerly, Director of GrassrootsHealth, ...
(Date:2/8/2016)... ... February 08, 2016 , ... The schedule is now online ... AutismOne 2016 Conference, which is being held May 25-29 at the Loews Chicago O’Hare ... helpful interventions and causes of chronic illness in children. , Very recent articles have ...
Breaking Medicine News(10 mins):